During papillomavirus infection, the E5 protein localizes in the cell Golgi apparatus and other endomembrane compartments. Cells transformed by E5 do not express major histocompatibility class I complex (MHC I) on the cell surface, while cells transformed by the other transforming proteins E6 and E7 do. In addition, the total amount of both MHC I protein and mRNA is reduced in E5-transformed cells. Here we show that expression of bovine papillomavirus E5 causes the retention of MHC I in the Golgi apparatus, thus preventing its transport to the cell surface. We ascribe this effect to a failure of acidification of the Golgi apparatus, as similar effects are observed in control cells treated with the ionophore monensin. Treatment of E5-transformed cells with either b-or g-interferon increases the synthesis of MHC I, showing that inhibition of MHC I expression by E5 is not irreversible. However, even after interferon treatment, MHC I, although increased in quantity, is not transported to the cell surface. E5 therefore affects MHC I at several levels, but prevention of MHC I transport to the cell surface appears to be the dominant effect. Lack of surface MHC I would have profound consequences for presentation of viral peptides to the immune system.
Introduction
Papillomaviruses (PV) are small DNA tumour viruses which infect mucosal and cutaneous epithelia where they induce benign hyperproliferative lesions. In most cases, papillomavirus infections are cleared after several months by a cell mediated immune response directed against viral antigens (Frazer and Tindle, 1996) . Occasionally, however, the lesions do not regress; failure of virus clearance is attributed to a poor immunological response and persistent viral infection poses a greater risk of neoplastic progression.
Together with E6 and E7, E5 is a transforming protein of PV. While E6 and E7 are the main oncoproteins of mucosal human papillomavirus (HPVs) (Mantovani and Banks, 2001; Munger et al., 2001 ), E5 is the major oncoprotein of bovine papillomaviruses (BPVs), particularly of BPV-1 (DiMaio and Mattoon, 2001) . The E5 protein is a small hydrophobic peptide (from 83 amino acid residues in HPV-16 to 42 residues in BPV-4), and recent data suggests that it is a type II membrane protein with one a-helical trans-membrane span in BPV E5 and up to three trans-membrane spans in HPV E5 (Surti et al., 1998) . It is expressed during the early stages of infection in the deep layers of the infected epithelium and its expression is extinguished as the lesion progresses (Burnett et al., 1992; Anderson et al., 1997; Chang et al., 2001) .
In agreement with its hydrophobic nature, E5 is localized in the endomembrane compartments of the endoplasmic reticulum (ER) and Golgi apparatus (GA) of the host cell (Burkhardt et al., 1989; Pennie et al., 1993) . The function of E5 in vivo is not known, but in vitro cell transformation is brought about by the activation of several kinases, from growth factor receptors to cyclins-cdks (Morgan and Campo, 2000) . E5 interacts physically with the cellular protein 16k ductin/subunit c, a component of the gap junction and of the V0 sector of the vacuolar H + -ATPase (Goldstein et al., 1991; Conrad et al., 1993; Finbow et al., 1995; Faccini et al., 1996) . This physical interaction has been deemed responsible for the down-regulation of gap junction communication (Oelze et al., 1995; Faccini et al., 1996; Ashrafi et al., 2000) and for the lack of acidification of endosomes and GA (Straight et al., 1995; Schapiro et al., 2000) . The inhibition of acidification of the endomembrane components has been attributed to a malfunction of the H + -ATPase (Briggs et al., 2001) , although lack of acidification of late endosomes or inhibition of the vacuolar proton pump are not always observed (Thomsen et al., 2000; Ashby et al., 2001) .
We have recently shown that transformed cells expressing BPV-1 or BPV-4 E5 are highly vacuolated (Ashrafi et al., 2000) and have an enlarged and often disrupted GA (Ashrafi et al., 2002) , and have attributed this morphology to the interaction of E5 and 16k subunit c. In these cells, E5 proteins, including E5 from HPV-16, cause down-regulation of the major histocompatibility class I (MHC I) complex (Ashrafi et al., 2002; O'Brien and Campo, 2002) , and this may contribute to PV escape from immunosurveillance and aid the establishment of viral infection.
Here we extend our observations on MHC I downregulation in BPV E5-transformed cells and report that E5 causes the retention of MHC I in the GA and prevents its export to the plasma membrane. The lack of surface expression of MHC I is observed even when the levels of MHC I heavy chain are increased by interferon treatment of E5 cells. The interference of E5 with MHC I transport is likely due to the lack of acidification of the GA in E5 cells, as similar effects are observed in non-transformed and non-E5 transformed control cells treated with the ionophore monensin.
Results

MHC I is retained in the GA in E5-transformed cells
MHC I is consistently absent from the cell surface in cells transformed by BPV-1 E5 (1-E5) or BPV-4 E5 (4-E5), as assessed by FACS analysis (Figure 1a ) (Ashrafi et al., 2002) . To ascertain the intracellular localization of MHC I in E5 cells, primary bovine cells (PalF), PalF cells transformed by E6 and E7 (designated no-E5) and by the addition of E5 (designated E5 cells) were stained with either mAb IL-A19 or IL-A88 (Bensaid et al., 1989; Toye et al., 1990) , which recognize b2-microglobulin-associated MHC I heavy chain or free heavy chain, respectively. In PalF and no-E5 cells, MHC I was detected on the cell surface and in a Golgi-like structure (Figure 1b) . In contrast in both 1-E5 and 4-E5 transformed cells, MHC I was detected only in abnormal structures (Figure 1b) , reminiscent of the misshapen GA in these cells (Ashrafi et al., 2002) . Similar results were obtained with either antibody (data not shown).
E5 and MHC I heavy chain co-localize in the GA
To define the intracellular structures in which MHC I was detected, PalF, no-E5 and 4-E5 cells were transfected with a plasmid encoding a fusion of green fluorescent protein (GFP) and MHC I heavy chain, and stained with the Golgi marker BODIPY-TRceramide. In all cell lines, GFP-MHC I heavy chain localized in the GA, which had the normal 'ring-like' To investigate whether E5 and MHC I co-localize, the cell lines were co-transfected with GFP-MHC I heavy chain and a plasmid encoding a fusion protein of the fluorescent protein DsRed and BPV-4 E5 (RFP-E5). Like wild type E5 (Pennie et al., 1993) , RFP-E5 localized in the GA (Figure 2b ), whereas DsRed on its own was distributed uniformly in the nucleus and cytoplasm (data not shown). In all cell lines, GFP-MHC I heavy chain co-localized with RFP-E5 in the GA (Figure 2b ).
Retention of MHC I in the GA by E5 is specific
It was important to demonstrate that retention of MHC I in the GA was specific, and not due, for instance, to the nature of the fusion proteins used in the study. Therefore, the cells were transfected with a plasmid expressing the papillomavirus E2 protein. As expected (Ham et al., 1991) , E2 localized in the nucleus in all cell lines, including 4-E5 transformed cells (Figure 3a) , showing that E5 did not retain a predominantly nuclear protein in the endomembrane compartment. Moreover, co-expression of E2 and GFP-MHC I heavy chain, or E2 and RFP-E5 did not lead to co-localization: E2 was nuclear in all cases, and MHC I heavy chain and E5 were localized in the GA (Figure 3b ).
Prevention of GA acidification by the ionophore monensin prevents transport of MHC I to the cell surface
The monovalent ionophore monensin is widely used to investigate the function of the GA and vesicular transport (see Barchet et al., 2001; Halaban et al., 2002; Schoonderwoert et al., 2002) . Monensin disperses the proton gradient across the cell membranes and impedes the proper acidification of Golgi cisternae by displacing and inhibiting the H + -V-ATPase proton pump, leading to GA swelling and fragmentation and faulty protein transport from the medial to the trans-Golgi (Tartakoff, 1983; Boss et al., 1984; Zhang et al., 1996; Chikuma et al., 2002) . E5 complexes with 16k subunit c, a component of the V0 sector of the H + -V-ATPase (Goldstein et al., 1991; Conrad et al., 1993; Faccini et al., 1996; Ashrafi et al., 2000) and inhibits endomembrane acidification (Straight et al., 1995; Schapiro et al., 2000) . In view of the similarity between the reported morphology of monensin-treated cells and E5 cells, and the functional similarity between monensin and E5, we treated PalF and no-E5 cells with monensin and analysed them for morphology, GA architecture and surface MHC I. Indeed, monensin-treated PalF cells or no-E5 cells showed extensive vacuolization and a grossly deformed GA (Figure 4a , shown only for PalF cells). These results indicate that the vacuolization and GA malformation in E5 cells are likely due to the impeded acidification of the GA membranes brought about by the viral protein.
Next we investigated whether treatment with monensin resulted in a down-regulation of surface MHC I in either PalF or no-E5 cells. Cells were treated with 25 mM monensin for 30 min, 3 or 12 h, and analysed for surface or total MHC I by FACS. Monensin treatment caused a fourfold decrease in surface MHC I after 30 min in PalF cells and after 3 h in no-E5 cells (Figure 4b ). The levels of surface MHC I returned to those seen in non-treated cells after 12 h in both cell lines (data not shown) in agreement with the reported ability of cells to recover from the effects of monensin treatment (Zhang et al., 1993) . We do not know why no-E5 cells down-regulated surface MHC I ; the delay may be due to the expression of the other oncoproteins present in no-E5 cells. The experiment was repeated three times and the ratio between the mean fluorescence for total and surface (T/ S) MHC I was calculated. The T/S ratio confirmed that monensin treatment reduces expression of surface MHC I: after 30 min of monensin treatment, the T/S ratio in PalF cells was increased approximately fourfold, and in no-E5 cells the highest T/S ratio was obtained after 3 h of treatment ( Figure 4b ). The transport to the cell surface of another membrane glycoprotein, the transferrin receptor, was not affected in E5 cells (Ashrafi et al., 2002) , and likewise there were no differences in the levels of surface transferrin receptor between cells treated and not treated with monensin (data not shown).
Monensin treatment did not significantly affect the levels of total MHC I in PalF cells and slightly decreased it in no-E5 cells, as judged by immunoblotting (Figure 4c ), and therefore we conclude that monensin inhibited the transport of MHC I to the cell surface but not its expression. These results indicate that, following inhibition of GA acidification by monensin, transport of MHC I to the cell surface is impeded, and support the notion that E5 prevents MHC I transport through inhibition of GA acidification.
Treatment of E5 cells with interferon increases total but not surface MHC I
Both b-interferon and g-interferon (b-IFN or g-IFN) increase the transcription activity of the MHC I heavy chain gene promoter (Agrawal and Kishore, 2000) leading to higher expression levels of heavy chain. We have previously shown that in E5 cells there is less MHC I heavy chain mRNA and protein (Ashrafi et al., 2002) . To see if the biosynthetic pathway of heavy chain is permanently inhibited by E5, we treated PalF, no-E5 and E5 cells with either b-or g-IFN or the control supernatant 2DG. Treatment with either IFN, but not with 2DG, noticeably increased production of the MHC I heavy chain to approximately the same extent in all cell lines as assessed by immunoblotting (Figure 5a ). This shows that E5 cells are responsive to IFN and the biosynthetic pathway of MHC I heavy chain is not irreversibly inhibited by E5. The IFN-treated cells were also analysed by FACS to ascertain whether the increased production of heavy chain led to a corresponding increase in surface MHC I. MHC I surface expression increased only in PalF and no-E5 cells but not in E5 cells, or in cells expressing the hypertransforming 4-E5 N17A mutant (Figure 5b ), despite the increase in total MHC I. These results unequivocally show that E5 inhibits the transport of 
Discussion
MHC class I molecules play a crucial role in immune recognition and clearance of virus infected cells. The proteolytic degradation of viral proteins generates a spectrum of peptides that are transported into the ER and loaded onto the MHC class I complex, which consists of the MHC I heavy chain and b2-microglobulin. Following transport from the ER through the GA to the cell surface, the MHC class I/peptide complexes are presented to virus-specific cytotoxic T lymphocytes (CTL), signalling virus infection and enabling killing of the infected cell. The importance of MHC class I molecules in virus clearance has been demonstrated by the identification of many mechanisms of interference with the MHC class I pathway evolved by viruses, from prevention of peptide processing to formation of non-functional MHC I complexes (Yewdell and Bennink, 1999) . In each of these strategies, the outcome is the failure by the infected cell to present viral peptide antigens to effector T cells and hence avoidance of detection and destruction by the host immune system. PV are poorly immunogenic. Even in immunocompetent hosts, whether animals or humans, PV persist for a significant period of time, usually spanning several months, before activation of the host immune system. This lack of recognition, in spite of the expression of abundant viral protein, suggests the host immune system is unaware of, or disabled by, PV infection. The ability of the virus to persist has been attributed to the nature of the virus life cycle, which may prevent the immune cells having access to the viral proteins (Tindle, 2002) . Although undoubtedly a factor in immune evasion, there is now increasing evidence that PV encode proteins that can directly subvert the host immune response, resulting in a delay in, or prevention of, resolution of infection . We have recently shown that the PV oncoprotein E5 can down-regulate the surface expression of MHC I, which may affect the recognition and killing of PV-infected cells by CTL (Ashrafi et al., 2002; O'Brien and Campo, 2002 ). E5 appears to interfere with several steps of the MHC I pathway, including transcription of MHC I heavy chain mRNA, expression of MHC I heavy chain protein, and In order to determine if the MHC I biosynthetic pathway was rendered irretrievably malfunctional by E5, we treated the cells with type I and II IFNs which are potent inducers of MHC I expression (Agrawal and Kishore, 2000) . All of the cell lines tested, including the E5 cells, responded to IFN treatment by increasing the level of MHC I heavy chain to approximately the same extent, although the effect was more marked with g-IFN than with b-IFN. Thus, although E5 reduces the levels of both mRNA and protein, transcription and translation of the MHC I heavy chain can be recovered showing that the effects of E5 on MHC I expression are not irreversible. What is clearly irreversibly impaired in E5 cells is the transport of MHC I to the cell periphery, as despite the marked increase in MHC I heavy chain, no MHC I is found on the surface of the IFN-treated E5 cells. E5 therefore retains MHC I intracellularly.
Both endogenous MHC I or exogenous (transfected) GFP-MHC I heavy chain fusion protein are retained in the swollen and misshapen GA characteristic of E5-expressing cells and indeed co-localized with the E5 protein in the GA. The detection of endogenous MHC I in the GA with mAb IL-A19, which does not recognize free MHC I heavy chain, indicates that the heavy chain is complexed with b2-microglobulin. This suggests that the arrest of MHC I transport occurs following MHC class I complex formation in the ER and is instead a fault in cellular transport across the Golgi compartments. Indeed, treatment of control cells with the ionophore monensin resulted in the acquisition of a phenotype remarkably similar to that of E5 cells, with many vacuoles and a distorted GA, with a concordant rapid and marked down-regulation of surface MHC I. Monensin is a well-characterized inhibitor of GA acidification, which hinders cellular transport of newly synthesized proteins, particularly interfering with transfer across Golgi compartments and compromising secretion from the medial to the trans-Golgi (Tartakoff, 1983) . Taking into account the similar functional effect of monensin and E5, we suggest that E5 causes GA malformation and retention of the MHC I complex in the GA by increasing GA pH.
However, the impeded transport of the MHC I complex in E5 cells is not part of a generalized disturbance of intracellular traffic as we have shown that the transport of the transferrin receptor is not affected by E5 expression (Ashrafi et al., 2002) nor by treatment with monensin. How then does E5 prevent Like E5, the HTLV-1 p12 I , another small hydrophobic viral protein, binds to the 16k subunit c component of the H + -V-ATPase (Franchini et al., 1993) . p12 I can also bind MHC I causing its intracytoplasmic retention and degradation (Johnson et al., 2001) . However, we feel that a physical interaction between E5 and MHC I is an unlikely cause of MHC I retention in the GA. E5 is expressed at a very low level in transformed cells (O'Brien et al., 1999) , and although IFN treatment markedly increases the expression of MHC I heavy chain, it has no effect on E5 expression (R Ullah et al., unpublished observations). Hence a one-to-one interaction between E5 and MHC I heavy chain is stochiometrically incompatible.
A more likely explanation may be that E5-induced acidification of the GA causes the incorrect glycosylation of the MHC I heavy chain. This hypothesis is supported by the observation that monensin disrupts the processing of N-and O-linked carbohydrates on glycoproteins and this disruption inhibits the intracellular transport of a variety of proteins (Anderson and Pathak, 1985) . Moreover, it has recently been reported that 16k subunit c suppresses the tumour-related glycosylation of cell surface receptors, and that this effect is independent of V-ATPase function (Skinner and Wildeman, 2001 ). Therefore, it is possible that the interaction of E5 with 16k subunit c may lead to improper glycosylation and processing of MHC I. Improperly processed MHC I molecules accumulate and are degraded in an expanded Golgi intermediate compartment (Raposo et al., 1995) , which is consistent with the cellular localization of the MHC class I complex in the E5 cells. In addition, degradation would account for the reduced amounts of MHC I heavy chain observed in E5 cells. It remains to be seen if inhibition of the E5-16k subunit c interaction can revert, at least partially, the transformed phenotype of E5 cells and restore surface MHC I expression.
Materials and methods
Cell lines
Primary embryonic bovine cells (PalF) transformed by PV E6 and E7 oncogenes, with or without BPV-1 or BPV-4 E5 (1-E5 or 4-E5 respectively), have been described previously (Ashrafi, 1998; O'Brien et al., 1999) . In these cells, the combination of BPV-4 E7, E5 from either BPV-1 or BPV-4, and activated ras induces cell transformation but immortalization is conferred by HPV-16 E6 (Pennie et al., 1993) , as the BPV-4 genome does not encode an E6 protein (Jackson et al., 1991) . Briefly, normal parental cells are designated PalF; cells transformed by E6, E7 and activated ras are designated 'no-E5' and cells transformed as above but with the addition of either E5 protein are designated 'E5'. The cell lines were grown in Dulbecco's modified Eagles medium (DMEM) (InVitrogen/Life Technologies, UK) containing 10% foetal calf serum (FCS) at 378C in 5% CO 2 , unless specified to the contrary.
Treatment of cells with monensin
PalF and no-E5 cells were treated with 25 mM monensin (Sigma, UK) for 30 min, 3 or 12 h. The morphology of the GA and surface MHC I were determined as described below.
Treatment of cells with interferon
One million PalF, no-E5 and E5-transformed cells were seeded in 100 mm diameter tissue culture dishes. The following day, the medium was replaced with fresh medium with or without 500 U/ml b-IFN (Sigma) or recombinant ovine g-IFN (Graham et al., 1995) . 2D6, a supernatant from cells not expressing IFN, was used as control. After 48 h, the cells were harvested for detection of MHC I by immunoblotting or FACS analysis (see below). Ovine recombinant g-IFN and 2D6 were a kind gift of Dr G Entrican (Moredun Research Institute, Penicuik, UK). 
Antibodies
Monoclonal antibody (mAb) 4A3 is raised against GM130, an integral GA protein (Barr et al., 1998) and was a kind gift of Dr Martin Lowe (University of Manchester, UK). MAbs IL-A19 and IL-A88 are raised against monomorphic determinant of bovine MHC I (Bensaid et al., 1989; Toye et al., 1990) , which recognize b2-microglobulin-associated MHC I heavy chain or free heavy chain, respectively. They are kind gifts of Dr Liz Glass (IAH, Roslin, UK) and Dr Shirley Ellis (IAH, Compton, UK), respectively. TVG261 recognizes the E2 protein of HPV-16 and was a kind gift of Dr Merilyn Hibma (University of Otago, New Zealand).
DNA transfection
Cells were aliquoted into 24-well plates containing coverslips at 10 4 cells/well and grown overnight to approximately 80% confluence. Plasmids (0.6 mg) were transfected into cells using LipofectAMINE PLUS TM Reagent (InVitrogen/Life Technologies, UK) according to the manufacturer's instructions. Forty-eight hours after transfection, the cells were washed twice with PBS and then fixed in 1.85% formaldehyde (Sigma) diluted in PBS containing 2% sucrose (Schwarz/ Mann, USA) for 10 min at room temperature. Following a further three washes with PBS, the coverslips were removed from the well and mounted in AF1 (Citifluor, UK).
Visualization of GFP and RFP plasmids
Cells expressing fluorescent GFP-MHC I and RFP-E5 were visualized either using a Leica DMLB microscope or a Zeiss LSM 510 microscope.
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Detection of E2
Cells were transfected with pCMVE2 and fixed 24 h after transfection as described above. Following washes in PBS, the cells were permeabilized in 0.5% NP40/PBS/10% sucrose for 10 min at room temperature and then washed three times with 1% FCS/PBS. The coverslips were incubated in mAb TVG261 for 1 h at room temperature, washed in 1% FCS/ PBS and then incubated with an anti-mouse antibody conjugated either with Texas Red or with FITC (Sigma). Following further washes in 1% FCS/PBS, coverslips were mounted in AF1 and analysed as above.
Visualization of Golgi apparatus
The GA was visualized by staining with BODIPY-TRceramide. Cells were grown until 80% confluent in single well chamber slides. After removal of medium cells were washed twice with serum free DMEM, 25 mM HEPES (DMEM-H) and incubated in 200 ml of 5 mM BODIPY-TRceramide, which localizes to the GA, in DMEM-H for 30 min at 48C. Cells were then washed with DMEM-H for 30 min at 378C. After removal of the medium and washing with PBS, cells were fixed with fresh 3% paraformaldehyde (PFA) for 20 min at room temperature and mounted with Vectashield (Vector Laboratories Inc, UK).
Cytoimmunofluorescent detection of Golgi apparatus and MHC I
The cells were washed twice with PBS and fixed with fresh 3% PFA in PBS for 20 min at room temperature. After the PFA fixation, a second fixation was performed by dipping the chamber slides in 7208C methanol for 4 min; then the cells were washed three times in PBS. For GA detection, the cells were incubated with mAb 4A3 for 30 min at room temperature, washed as above and incubated with AlexaFluorTM 488 goat anti-mouse IgG(H+L) conjugate (Molecular Probes, Europe BV) for 30 min at room temperature. For the detection of endogenous surface MHC I, the cells were incubated with mAb IL-A19 or mAb IL-A88 for 1 h at room temperature and washed three times as above. The cells were then incubated with anti-mouse IgG-FITC (Sigma) at 48C for 1 h in the dark. Following three final washes with PBS, the slides were mounted in PBS and analysed under the fluorescence microscope.
Detection of MHC class I by FACS
Cells were grown in a 175 cm 2 flask to approximately 80% confluence. After removal of the medium, the cells were washed once with PBS, then detached from the flask with trypsin/EDTA and pelleted at 200 g for 5 min at room temperature. The cell pellet was resuspended in DMEM, 10% FCS, for 1 h at 378C to allow surface antigens to be reexpressed. The cells were washed and re-suspended in PBS-1% BSA (PBS-B) at 10 7 cells/ml. For the detection of surface MHC I, 100 ml of cells were aliquoted and incubated with an equal volume of mAb IL-A19 for 30 min at 48C. The cells were washed three times in PBS-B and incubated with antimouse IgG-FITC (Sigma) at 48C for 30 min in the dark. The cells were washed and resuspended in 500 ml PBS-B and analysed by flow cytometry. If the flow cytometry analysis was not carried out immediately, the cells were resuspended in 500 ml of 3% PFA in PBS and kept at 48C.
For the detection of intracellular MHC I, the cells were fixed in 3% PFA in PBS for 20 min at room temperature, washed in PBS-B and permeabilized with 0.5% saponin in PBS-B for 30 min at room temperature. Following a further wash in PBS-B, the permeabilized cells were stained with mAb IL-A19 as described above. All samples were examined in a Beckman Coulter EPICS Elite analyser equipped with an ion argon laser with 15 mV of excitation at 488 nm. The data were analysed using Expo 2 software.
Detection of MHC I by immunoblotting
Cells were removed from the flasks by trypsinization, washed with PBS, then lysed by sonication in lysis buffer (100 mM Tris HCl, pH 7.5, 2% SDS, 20% glycerol) and insoluble material was removed by centrifugation at 20 000 g. Ten mg of lysate were electrophoresed in 4 -12% NuPAGE gels (InVitrogen), and proteins transferred to nitrocellulose membrane (InVitrogen) using a semidry blotting apparatus at 20 V/150 A for 1 h. The membranes were blocked in 5% milk/TBS/Tween 20 (0.05%) at room temperature for 1 h before incubation with mAb IL-A88, or mAb AB-1 (Calbiochem) specific for actin. After repeated washing with TBS/Tween 20 (0.05%) the membranes were incubated with anti-mouse Ig-HRP (Amersham Pharmacia Biotech, UK) for mAB IL-A88, and anti-mouse IgM-HRP (Oncogene Calbiochem-Novabiochem International) for mAb AB-1, in 5% milk/TBS/Tween 20 (0.05%) for 1 h at room temperature. The membranes were washed three times with TBS/Tween 20 (0.05%) and bound antibody was detected by enhanced chemoluminescence staining (ECL) (Amersham Pharmacia Biotech).
